MedTrace Logo

Phase 2, Multi-Center Trial of Modafinil for Methamphetamine Dependence

NCT00520286 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 210

Last updated 2017-04-07

Study results available
· View outcomes & findings →

Summary

The purpose of this study will be to examine the safety and efficacy of modafinil in increasing number of methamphetamine non-use weeks in subjects with methamphetamine dependence.

Conditions

  • Methamphetamine Dependence

Interventions

DRUG

Modafinil

200 mg or 400 mg /daily

DRUG

Placebo

Placebo / daily

Sponsors & Collaborators

  • VA Office of Research and Development

    collaborator FED

  • National Institute on Drug Abuse (NIDA)

    lead NIH

Principal Investigators

  • Ahmed Elkashef, M.D. · National Institute on Drug Abuse (NIDA)

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2007-12-31
Primary Completion
2009-12-31
Completion
2010-03-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00520286 on ClinicalTrials.gov